Journal article
Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy
Drug, Healthcare and Patient Safety, Vol.4(1), pp.81-86
2012
DOI: 10.2147/DHPS.S28814
PMCID: PMC3413039
PMID: 22888276
Abstract
One-third of patients with epilepsy continue to have seizures despite current treatments, indicating the need for better antiseizure medications with novel mechanisms of action. Ezogabine (retigabine) has recently been approved for adjunctive treatment of partial-onset seizures in adult patients with epilepsy. Ezogabine utilizes a novel mechanism of action, involving activation of specific potassium channels. The most common side effects of ezogabine are shared by most antiseizure medications and primarily consist of central nervous system (CNS) symptoms, such as somnolence, dizziness, confusion, and fatigue. In addition, a small percentage of patients on ezogabine experience a unique adverse effect affecting the bladder, which results in urinary hesitancy; thus, patients on ezogabine should be monitored carefully for potential urological symptoms. Overall, ezogabine appears to be well tolerated and represents a reasonable new option for treating patients with intractable epilepsy.
Details
- Title: Subtitle
- Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy
- Creators
- Michael A CilibertoJudith LZ WeisenbergMichael Wong
- Resource Type
- Journal article
- Publication Details
- Drug, Healthcare and Patient Safety, Vol.4(1), pp.81-86
- DOI
- 10.2147/DHPS.S28814
- PMID
- 22888276
- PMCID
- PMC3413039
- NLM abbreviation
- Drug Healthc Patient Saf
- ISSN
- 1179-1365
- eISSN
- 1179-1365
- Publisher
- Dove Medical Press
- Language
- English
- Date published
- 2012
- Academic Unit
- Neurology; Stead Family Department of Pediatrics; Neurology (Pediatrics)
- Record Identifier
- 9983905529402771
Metrics
19 Record Views